Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté

NCT ID: NCT02626377

Last Updated: 2023-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medical progress and modification of lifestyles have prolonged life expectancy, despite the development of chronic diseases. The support and care are often provided by a network of informal caregivers composed of family, friends, and neighbors. They became essential to help maintening the elderly persons to live at home. It has been demonstrated that the importance and the diversity of informal tasks may jeopardize their own physical, mental and social well-being.

The aim of the Informal Carers of Elderly Cohort is to define, through a longitudinal study of their life course, the profiles of caregivers of patients with a diagnosis of one of the following diseases: cancer (breast, prostate, colon-rectum), neuro-degenerative diseases (Parkinson's disease, Alzheimer's and similar diseases), neuro-vascular diseases (Cerebrovascular Accident (CVA)), Age-related Macular Degeneration(AMD) and heart disease (heart failure), aged ≥ 60 years old and living in Burgundy or Franche-Comte. By following the different phases of the caregiving relationship from the announcement of the diagnosis, it will be possible to assess the quality of life of caregivers and evaluate the implementation of a pragmatic social action to help informal caregivers through a randomized intervention trial nested in the cohort.

Thanks to an analytical and longitudinal definition of the profiles of informal caregivers, this study could gather precise information on their life courses and their health trajectory by identifying the consequences associated with the concept of their role of aid in care. In addition, the randomized intervention trial will explore the efficacy, in terms of quality of life, and efficiency of a social action to support the caregivers. These data will allow to identify strategies that could be used to improve the existing sources of aid and to propose new approaches to help caregivers. This study will provide the opportunity to identify the most relevant means of support and to give an impulse for new healthcare policies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Colorectal Cancer Prostate Cancer Alzheimer Disease Age-related Macular Degeneration Parkinson Disease Cardiac Disease Ischemic Stroke Hemorrhagic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional arm

'Support provided by social worker'

Group Type EXPERIMENTAL

Support provided by social worker

Intervention Type BEHAVIORAL

Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.

Information booklet receipt

Intervention Type OTHER

Caregivers will only receive an information booklet (which informs about existing structures and actions)

Non-interventional arm

'Information booklet receipt'

Group Type OTHER

Information booklet receipt

Intervention Type OTHER

Caregivers will only receive an information booklet (which informs about existing structures and actions)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Support provided by social worker

Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.

Intervention Type BEHAVIORAL

Information booklet receipt

Caregivers will only receive an information booklet (which informs about existing structures and actions)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To be able to identify a principal caregiver via a specific questionnaire (if the patient is unable to identify himself his caregiver due to the disease, a self-designation form as a principal caregiver will be allow and propose)
* to accept to complete the questionnaire to designate the principal caregiver;
* To live in either Burgundy-Franche-Comte county;
* have been recently diagnosed at hospital or in private-sector for the following diseases: Local or metastatic cancer diagnosed less than 6 month (breast cancer-hormone sensitive- in first line chemotherapy treatment, hormone-sensitive prostate cancer or in metastatic recurrence after 3 years of remission, considered as a new case, colorectal cancer in first line chemotherapy treatment), a neuro-degenerative disease (Parkinson disease diagnosed less than 7 years, Alzheimer disease and similar diseases diagnosed less than 12 months and /or with a Mini Mental State Examination (MMSE)\<24 and \>10 (performed less than 3 mois)), Age-related Macular Degeneration,( geographic atrophy or neovascular, diagnosed less than 12 month with an acuity range between 2 and 6/10e, be at least 65 years old and have received less than 3 sessions of intravitreal injections (IVT)), cardiac disease (heart failure diagnosed less than 3 months), neuro-vascular disease (ischemic or hemorrhagic stroke with clinical evidence of post stroke lesions upper than 24 hours, diagnosed less than 6 months and with a Rankin's score inferior or equal to 2).


* to be a member of the patient's social environment (family, friend and neighbor);
* to be identify by the patient as the "principal caregiver" based on the designation questionnaire or to have complete the self-designation form as a principal caregiver;
* ≥ 18 years old;
* not be an employee of a healthcare organization;
* living in Burgundy-Franche-Comte;
* to be able to complete questionnaires,

Exclusion Criteria

* previously diagnosed with another targeted disease and/or living in retirement home could not be included

Caregiver


\- to be under guardianship, curatorship or under the protection of justice
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Methodological and quality of life unit in oncology (CHRU de Besançon)

UNKNOWN

Sponsor Role collaborator

University of Franche-Comté

OTHER

Sponsor Role collaborator

University of Burgundy

OTHER

Sponsor Role collaborator

Pôle de Gérontologie Interrégional Bourgogne et Franche-Comté

UNKNOWN

Sponsor Role collaborator

CARSAT Bourgogne et Franche-Comté

UNKNOWN

Sponsor Role collaborator

CCAS of Dijon

UNKNOWN

Sponsor Role collaborator

CCAS of Besançon

UNKNOWN

Sponsor Role collaborator

CCAS of Montbéliard

UNKNOWN

Sponsor Role collaborator

Burgundy Regional Council

UNKNOWN

Sponsor Role collaborator

Franche-Comté Regional Council

UNKNOWN

Sponsor Role collaborator

The Municipality of Besançon

UNKNOWN

Sponsor Role collaborator

The Municipality of Dijon

UNKNOWN

Sponsor Role collaborator

General Council of the Doubs

UNKNOWN

Sponsor Role collaborator

General Council of the Territoire de Belfort

UNKNOWN

Sponsor Role collaborator

Collectif Inter Associatif Sur la Sante Bourgogne

UNKNOWN

Sponsor Role collaborator

Union Régionale Interfédérale des Œuvres et Organismes Privés Sanitaires Bourgogne

UNKNOWN

Sponsor Role collaborator

Association Gérontopôle Pierre Pfitzenmeyer

UNKNOWN

Sponsor Role collaborator

Pôle de compétitivité Vitagora Goût-Nutrition-Santé

UNKNOWN

Sponsor Role collaborator

National Old Age Insurance Fund for Employees (CNAVTS)

OTHER

Sponsor Role collaborator

Sheerbrooke Gérontopôle

UNKNOWN

Sponsor Role collaborator

France Alzheimer

OTHER

Sponsor Role collaborator

Institut Régional de Vieillissement (IRV)

UNKNOWN

Sponsor Role collaborator

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role collaborator

Roche Foundation

UNKNOWN

Sponsor Role collaborator

Ligue contre le cancer, France

OTHER

Sponsor Role collaborator

National Cancer Institute, France

OTHER_GOV

Sponsor Role collaborator

Quality of life and cancer clinical research platform

UNKNOWN

Sponsor Role collaborator

National Research Agency, France

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Virginie NERICH, Dr

Role: PRINCIPAL_INVESTIGATOR

Pôle Pharmaceutique CHU de Besançon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU de Besançon

Besançon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Pozet A, Falcoz A, Roller C, Jai T, Meurisse A, Nerich V. Health-state utility values and their time to deterioration in informal caregivers of older patients with chronic diseases. Front Public Health. 2025 Apr 30;13:1531608. doi: 10.3389/fpubh.2025.1531608. eCollection 2025.

Reference Type DERIVED
PMID: 40371298 (View on PubMed)

Pozet A, Darnis S, Bonnet M, Meurisse A, Dabakuyo-Yonli TS, Lejeune C, Fagnoni P, Gaimard M, Manckoundia P, Quibel C, Marchand M, Anota A, Nerich V. Quality of Life and Needs in Caregivers: Results From the Prospective Multicentric Open-Label Randomized Study of Informal Caregivers of Elderly Patients. Int J Public Health. 2023 Aug 30;68:1605459. doi: 10.3389/ijph.2023.1605459. eCollection 2023.

Reference Type DERIVED
PMID: 37711159 (View on PubMed)

Pozet A, Lejeune C, Bonnet M, Dabakuyo S, Dion M, Fagnoni P, Gaimard M, Imbert G, Nerich V, Foubert A, Chotard M, Bonin M, Anota A, Bonnetain F. Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Study): study protocol for a randomized controlled trial. Trials. 2016 Nov 3;17(1):531. doi: 10.1186/s13063-016-1622-8.

Reference Type DERIVED
PMID: 27881145 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P/2014/231

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.